INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13801, 13991, 'Oxacillin', 'Kidney Diseases', 'Oxacillin is partially converted by the liver to active and inactive metabolites, and both parent drug and metabolites are eliminated by the kidney.  The serum concentrations of oxacillin and its metabolites may be increased and the half-lives prolonged in patients with significantly impaired renal function.  In general, dosage adjustments are not necessary in either renal or hepatic impairment, but the lower range of the usual recommended dosage may be appropriate in patients with severe renal impairment (CrCl < 10 mL/min).  Renal and liver function tests should be performed periodically during prolonged therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13802, 13992, 'Oxacillin', 'Kidney Diseases', 'Oxacillin is partially converted by the liver to active and inactive metabolites, and both parent drug and metabolites are eliminated by the kidney.  The serum concentrations of oxacillin and its metabolites may be increased and the half-lives prolonged in patients with significantly impaired renal function.  In general, dosage adjustments are not necessary in either renal or hepatic impairment, but the lower range of the usual recommended dosage may be appropriate in patients with severe renal impairment (CrCl < 10 mL/min).  Renal and liver function tests should be performed periodically during prolonged therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13803, 16673, 'Oxacillin', 'Kidney Diseases', 'Oxacillin is partially converted by the liver to active and inactive metabolites, and both parent drug and metabolites are eliminated by the kidney.  The serum concentrations of oxacillin and its metabolites may be increased and the half-lives prolonged in patients with significantly impaired renal function.  In general, dosage adjustments are not necessary in either renal or hepatic impairment, but the lower range of the usual recommended dosage may be appropriate in patients with severe renal impairment (CrCl < 10 mL/min).  Renal and liver function tests should be performed periodically during prolonged therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13804, 16939, 'Oxacillin', 'Kidney Diseases', 'Oxacillin is partially converted by the liver to active and inactive metabolites, and both parent drug and metabolites are eliminated by the kidney.  The serum concentrations of oxacillin and its metabolites may be increased and the half-lives prolonged in patients with significantly impaired renal function.  In general, dosage adjustments are not necessary in either renal or hepatic impairment, but the lower range of the usual recommended dosage may be appropriate in patients with severe renal impairment (CrCl < 10 mL/min).  Renal and liver function tests should be performed periodically during prolonged therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13805, 16940, 'Oxacillin', 'Kidney Diseases', 'Oxacillin is partially converted by the liver to active and inactive metabolites, and both parent drug and metabolites are eliminated by the kidney.  The serum concentrations of oxacillin and its metabolites may be increased and the half-lives prolonged in patients with significantly impaired renal function.  In general, dosage adjustments are not necessary in either renal or hepatic impairment, but the lower range of the usual recommended dosage may be appropriate in patients with severe renal impairment (CrCl < 10 mL/min).  Renal and liver function tests should be performed periodically during prolonged therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13806, 18789, 'Oxacillin', 'Kidney Diseases', 'Oxacillin is partially converted by the liver to active and inactive metabolites, and both parent drug and metabolites are eliminated by the kidney.  The serum concentrations of oxacillin and its metabolites may be increased and the half-lives prolonged in patients with significantly impaired renal function.  In general, dosage adjustments are not necessary in either renal or hepatic impairment, but the lower range of the usual recommended dosage may be appropriate in patients with severe renal impairment (CrCl < 10 mL/min).  Renal and liver function tests should be performed periodically during prolonged therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13807, 19197, 'Oxacillin', 'Kidney Diseases', 'Oxacillin is partially converted by the liver to active and inactive metabolites, and both parent drug and metabolites are eliminated by the kidney.  The serum concentrations of oxacillin and its metabolites may be increased and the half-lives prolonged in patients with significantly impaired renal function.  In general, dosage adjustments are not necessary in either renal or hepatic impairment, but the lower range of the usual recommended dosage may be appropriate in patients with severe renal impairment (CrCl < 10 mL/min).  Renal and liver function tests should be performed periodically during prolonged therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13808, 19218, 'Oxacillin', 'Kidney Diseases', 'Oxacillin is partially converted by the liver to active and inactive metabolites, and both parent drug and metabolites are eliminated by the kidney.  The serum concentrations of oxacillin and its metabolites may be increased and the half-lives prolonged in patients with significantly impaired renal function.  In general, dosage adjustments are not necessary in either renal or hepatic impairment, but the lower range of the usual recommended dosage may be appropriate in patients with severe renal impairment (CrCl < 10 mL/min).  Renal and liver function tests should be performed periodically during prolonged therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13809, 19222, 'Oxacillin', 'Kidney Diseases', 'Oxacillin is partially converted by the liver to active and inactive metabolites, and both parent drug and metabolites are eliminated by the kidney.  The serum concentrations of oxacillin and its metabolites may be increased and the half-lives prolonged in patients with significantly impaired renal function.  In general, dosage adjustments are not necessary in either renal or hepatic impairment, but the lower range of the usual recommended dosage may be appropriate in patients with severe renal impairment (CrCl < 10 mL/min).  Renal and liver function tests should be performed periodically during prolonged therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13810, 19225, 'Oxacillin', 'Kidney Diseases', 'Oxacillin is partially converted by the liver to active and inactive metabolites, and both parent drug and metabolites are eliminated by the kidney.  The serum concentrations of oxacillin and its metabolites may be increased and the half-lives prolonged in patients with significantly impaired renal function.  In general, dosage adjustments are not necessary in either renal or hepatic impairment, but the lower range of the usual recommended dosage may be appropriate in patients with severe renal impairment (CrCl < 10 mL/min).  Renal and liver function tests should be performed periodically during prolonged therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13811, 20036, 'Oxacillin', 'Kidney Diseases', 'Oxacillin is partially converted by the liver to active and inactive metabolites, and both parent drug and metabolites are eliminated by the kidney.  The serum concentrations of oxacillin and its metabolites may be increased and the half-lives prolonged in patients with significantly impaired renal function.  In general, dosage adjustments are not necessary in either renal or hepatic impairment, but the lower range of the usual recommended dosage may be appropriate in patients with severe renal impairment (CrCl < 10 mL/min).  Renal and liver function tests should be performed periodically during prolonged therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13812, 24655, 'Oxacillin', 'Kidney Diseases', 'Oxacillin is partially converted by the liver to active and inactive metabolites, and both parent drug and metabolites are eliminated by the kidney.  The serum concentrations of oxacillin and its metabolites may be increased and the half-lives prolonged in patients with significantly impaired renal function.  In general, dosage adjustments are not necessary in either renal or hepatic impairment, but the lower range of the usual recommended dosage may be appropriate in patients with severe renal impairment (CrCl < 10 mL/min).  Renal and liver function tests should be performed periodically during prolonged therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13813, 521, 'Oxacillin', 'Water-Electrolyte Imbalance', 'Each gram of parenteral oxacillin sodium contains approximately 64 to 71 mg (2.8 to 3.1 mEq) of sodium and is buffered with 40 mg of dibasic sodium phosphate.  Each 250 mg capsule of oxacillin sodium contains approximately 16 mg (0.7 mEq) of sodium, and each teaspoonful of the 250 mg/5 mL oral solution contains approximately 18 mg (0.8 mEq) of sodium.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  In addition, hypokalemia has been reported rarely during therapy with the penicillinase-resistant penicillins, which may be particularly important to bear in mind when treating patients with low potassium reserves or fluid and electrolyte imbalance.  Clinical monitoring of electrolytes is recommended if these agents are used for prolonged periods.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13814, 522, 'Oxacillin', 'Water-Electrolyte Imbalance', 'Each gram of parenteral oxacillin sodium contains approximately 64 to 71 mg (2.8 to 3.1 mEq) of sodium and is buffered with 40 mg of dibasic sodium phosphate.  Each 250 mg capsule of oxacillin sodium contains approximately 16 mg (0.7 mEq) of sodium, and each teaspoonful of the 250 mg/5 mL oral solution contains approximately 18 mg (0.8 mEq) of sodium.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  In addition, hypokalemia has been reported rarely during therapy with the penicillinase-resistant penicillins, which may be particularly important to bear in mind when treating patients with low potassium reserves or fluid and electrolyte imbalance.  Clinical monitoring of electrolytes is recommended if these agents are used for prolonged periods.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13815, 609, 'Oxacillin', 'Water-Electrolyte Imbalance', 'Each gram of parenteral oxacillin sodium contains approximately 64 to 71 mg (2.8 to 3.1 mEq) of sodium and is buffered with 40 mg of dibasic sodium phosphate.  Each 250 mg capsule of oxacillin sodium contains approximately 16 mg (0.7 mEq) of sodium, and each teaspoonful of the 250 mg/5 mL oral solution contains approximately 18 mg (0.8 mEq) of sodium.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  In addition, hypokalemia has been reported rarely during therapy with the penicillinase-resistant penicillins, which may be particularly important to bear in mind when treating patients with low potassium reserves or fluid and electrolyte imbalance.  Clinical monitoring of electrolytes is recommended if these agents are used for prolonged periods.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13816, 610, 'Oxacillin', 'Water-Electrolyte Imbalance', 'Each gram of parenteral oxacillin sodium contains approximately 64 to 71 mg (2.8 to 3.1 mEq) of sodium and is buffered with 40 mg of dibasic sodium phosphate.  Each 250 mg capsule of oxacillin sodium contains approximately 16 mg (0.7 mEq) of sodium, and each teaspoonful of the 250 mg/5 mL oral solution contains approximately 18 mg (0.8 mEq) of sodium.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  In addition, hypokalemia has been reported rarely during therapy with the penicillinase-resistant penicillins, which may be particularly important to bear in mind when treating patients with low potassium reserves or fluid and electrolyte imbalance.  Clinical monitoring of electrolytes is recommended if these agents are used for prolonged periods.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13817, 611, 'Oxacillin', 'Water-Electrolyte Imbalance', 'Each gram of parenteral oxacillin sodium contains approximately 64 to 71 mg (2.8 to 3.1 mEq) of sodium and is buffered with 40 mg of dibasic sodium phosphate.  Each 250 mg capsule of oxacillin sodium contains approximately 16 mg (0.7 mEq) of sodium, and each teaspoonful of the 250 mg/5 mL oral solution contains approximately 18 mg (0.8 mEq) of sodium.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  In addition, hypokalemia has been reported rarely during therapy with the penicillinase-resistant penicillins, which may be particularly important to bear in mind when treating patients with low potassium reserves or fluid and electrolyte imbalance.  Clinical monitoring of electrolytes is recommended if these agents are used for prolonged periods.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13818, 612, 'Oxacillin', 'Water-Electrolyte Imbalance', 'Each gram of parenteral oxacillin sodium contains approximately 64 to 71 mg (2.8 to 3.1 mEq) of sodium and is buffered with 40 mg of dibasic sodium phosphate.  Each 250 mg capsule of oxacillin sodium contains approximately 16 mg (0.7 mEq) of sodium, and each teaspoonful of the 250 mg/5 mL oral solution contains approximately 18 mg (0.8 mEq) of sodium.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  In addition, hypokalemia has been reported rarely during therapy with the penicillinase-resistant penicillins, which may be particularly important to bear in mind when treating patients with low potassium reserves or fluid and electrolyte imbalance.  Clinical monitoring of electrolytes is recommended if these agents are used for prolonged periods.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13819, 4968, 'Oxacillin', 'Water-Electrolyte Imbalance', 'Each gram of parenteral oxacillin sodium contains approximately 64 to 71 mg (2.8 to 3.1 mEq) of sodium and is buffered with 40 mg of dibasic sodium phosphate.  Each 250 mg capsule of oxacillin sodium contains approximately 16 mg (0.7 mEq) of sodium, and each teaspoonful of the 250 mg/5 mL oral solution contains approximately 18 mg (0.8 mEq) of sodium.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  In addition, hypokalemia has been reported rarely during therapy with the penicillinase-resistant penicillins, which may be particularly important to bear in mind when treating patients with low potassium reserves or fluid and electrolyte imbalance.  Clinical monitoring of electrolytes is recommended if these agents are used for prolonged periods.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13820, 4985, 'Oxacillin', 'Water-Electrolyte Imbalance', 'Each gram of parenteral oxacillin sodium contains approximately 64 to 71 mg (2.8 to 3.1 mEq) of sodium and is buffered with 40 mg of dibasic sodium phosphate.  Each 250 mg capsule of oxacillin sodium contains approximately 16 mg (0.7 mEq) of sodium, and each teaspoonful of the 250 mg/5 mL oral solution contains approximately 18 mg (0.8 mEq) of sodium.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  In addition, hypokalemia has been reported rarely during therapy with the penicillinase-resistant penicillins, which may be particularly important to bear in mind when treating patients with low potassium reserves or fluid and electrolyte imbalance.  Clinical monitoring of electrolytes is recommended if these agents are used for prolonged periods.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13821, 4986, 'Oxacillin', 'Water-Electrolyte Imbalance', 'Each gram of parenteral oxacillin sodium contains approximately 64 to 71 mg (2.8 to 3.1 mEq) of sodium and is buffered with 40 mg of dibasic sodium phosphate.  Each 250 mg capsule of oxacillin sodium contains approximately 16 mg (0.7 mEq) of sodium, and each teaspoonful of the 250 mg/5 mL oral solution contains approximately 18 mg (0.8 mEq) of sodium.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  In addition, hypokalemia has been reported rarely during therapy with the penicillinase-resistant penicillins, which may be particularly important to bear in mind when treating patients with low potassium reserves or fluid and electrolyte imbalance.  Clinical monitoring of electrolytes is recommended if these agents are used for prolonged periods.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13822, 4988, 'Oxacillin', 'Water-Electrolyte Imbalance', 'Each gram of parenteral oxacillin sodium contains approximately 64 to 71 mg (2.8 to 3.1 mEq) of sodium and is buffered with 40 mg of dibasic sodium phosphate.  Each 250 mg capsule of oxacillin sodium contains approximately 16 mg (0.7 mEq) of sodium, and each teaspoonful of the 250 mg/5 mL oral solution contains approximately 18 mg (0.8 mEq) of sodium.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  In addition, hypokalemia has been reported rarely during therapy with the penicillinase-resistant penicillins, which may be particularly important to bear in mind when treating patients with low potassium reserves or fluid and electrolyte imbalance.  Clinical monitoring of electrolytes is recommended if these agents are used for prolonged periods.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13823, 4989, 'Oxacillin', 'Water-Electrolyte Imbalance', 'Each gram of parenteral oxacillin sodium contains approximately 64 to 71 mg (2.8 to 3.1 mEq) of sodium and is buffered with 40 mg of dibasic sodium phosphate.  Each 250 mg capsule of oxacillin sodium contains approximately 16 mg (0.7 mEq) of sodium, and each teaspoonful of the 250 mg/5 mL oral solution contains approximately 18 mg (0.8 mEq) of sodium.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  In addition, hypokalemia has been reported rarely during therapy with the penicillinase-resistant penicillins, which may be particularly important to bear in mind when treating patients with low potassium reserves or fluid and electrolyte imbalance.  Clinical monitoring of electrolytes is recommended if these agents are used for prolonged periods.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13824, 5008, 'Oxacillin', 'Water-Electrolyte Imbalance', 'Each gram of parenteral oxacillin sodium contains approximately 64 to 71 mg (2.8 to 3.1 mEq) of sodium and is buffered with 40 mg of dibasic sodium phosphate.  Each 250 mg capsule of oxacillin sodium contains approximately 16 mg (0.7 mEq) of sodium, and each teaspoonful of the 250 mg/5 mL oral solution contains approximately 18 mg (0.8 mEq) of sodium.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  In addition, hypokalemia has been reported rarely during therapy with the penicillinase-resistant penicillins, which may be particularly important to bear in mind when treating patients with low potassium reserves or fluid and electrolyte imbalance.  Clinical monitoring of electrolytes is recommended if these agents are used for prolonged periods.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13825, 5012, 'Oxacillin', 'Water-Electrolyte Imbalance', 'Each gram of parenteral oxacillin sodium contains approximately 64 to 71 mg (2.8 to 3.1 mEq) of sodium and is buffered with 40 mg of dibasic sodium phosphate.  Each 250 mg capsule of oxacillin sodium contains approximately 16 mg (0.7 mEq) of sodium, and each teaspoonful of the 250 mg/5 mL oral solution contains approximately 18 mg (0.8 mEq) of sodium.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  In addition, hypokalemia has been reported rarely during therapy with the penicillinase-resistant penicillins, which may be particularly important to bear in mind when treating patients with low potassium reserves or fluid and electrolyte imbalance.  Clinical monitoring of electrolytes is recommended if these agents are used for prolonged periods.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13826, 5014, 'Oxacillin', 'Water-Electrolyte Imbalance', 'Each gram of parenteral oxacillin sodium contains approximately 64 to 71 mg (2.8 to 3.1 mEq) of sodium and is buffered with 40 mg of dibasic sodium phosphate.  Each 250 mg capsule of oxacillin sodium contains approximately 16 mg (0.7 mEq) of sodium, and each teaspoonful of the 250 mg/5 mL oral solution contains approximately 18 mg (0.8 mEq) of sodium.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  In addition, hypokalemia has been reported rarely during therapy with the penicillinase-resistant penicillins, which may be particularly important to bear in mind when treating patients with low potassium reserves or fluid and electrolyte imbalance.  Clinical monitoring of electrolytes is recommended if these agents are used for prolonged periods.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13827, 5015, 'Oxacillin', 'Water-Electrolyte Imbalance', 'Each gram of parenteral oxacillin sodium contains approximately 64 to 71 mg (2.8 to 3.1 mEq) of sodium and is buffered with 40 mg of dibasic sodium phosphate.  Each 250 mg capsule of oxacillin sodium contains approximately 16 mg (0.7 mEq) of sodium, and each teaspoonful of the 250 mg/5 mL oral solution contains approximately 18 mg (0.8 mEq) of sodium.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  In addition, hypokalemia has been reported rarely during therapy with the penicillinase-resistant penicillins, which may be particularly important to bear in mind when treating patients with low potassium reserves or fluid and electrolyte imbalance.  Clinical monitoring of electrolytes is recommended if these agents are used for prolonged periods.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13828, 6085, 'Oxacillin', 'Water-Electrolyte Imbalance', 'Each gram of parenteral oxacillin sodium contains approximately 64 to 71 mg (2.8 to 3.1 mEq) of sodium and is buffered with 40 mg of dibasic sodium phosphate.  Each 250 mg capsule of oxacillin sodium contains approximately 16 mg (0.7 mEq) of sodium, and each teaspoonful of the 250 mg/5 mL oral solution contains approximately 18 mg (0.8 mEq) of sodium.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  In addition, hypokalemia has been reported rarely during therapy with the penicillinase-resistant penicillins, which may be particularly important to bear in mind when treating patients with low potassium reserves or fluid and electrolyte imbalance.  Clinical monitoring of electrolytes is recommended if these agents are used for prolonged periods.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13829, 13988, 'Oxacillin', 'Water-Electrolyte Imbalance', 'Each gram of parenteral oxacillin sodium contains approximately 64 to 71 mg (2.8 to 3.1 mEq) of sodium and is buffered with 40 mg of dibasic sodium phosphate.  Each 250 mg capsule of oxacillin sodium contains approximately 16 mg (0.7 mEq) of sodium, and each teaspoonful of the 250 mg/5 mL oral solution contains approximately 18 mg (0.8 mEq) of sodium.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  In addition, hypokalemia has been reported rarely during therapy with the penicillinase-resistant penicillins, which may be particularly important to bear in mind when treating patients with low potassium reserves or fluid and electrolyte imbalance.  Clinical monitoring of electrolytes is recommended if these agents are used for prolonged periods.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13830, 13990, 'Oxacillin', 'Water-Electrolyte Imbalance', 'Each gram of parenteral oxacillin sodium contains approximately 64 to 71 mg (2.8 to 3.1 mEq) of sodium and is buffered with 40 mg of dibasic sodium phosphate.  Each 250 mg capsule of oxacillin sodium contains approximately 16 mg (0.7 mEq) of sodium, and each teaspoonful of the 250 mg/5 mL oral solution contains approximately 18 mg (0.8 mEq) of sodium.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  In addition, hypokalemia has been reported rarely during therapy with the penicillinase-resistant penicillins, which may be particularly important to bear in mind when treating patients with low potassium reserves or fluid and electrolyte imbalance.  Clinical monitoring of electrolytes is recommended if these agents are used for prolonged periods.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13831, 13991, 'Oxacillin', 'Water-Electrolyte Imbalance', 'Each gram of parenteral oxacillin sodium contains approximately 64 to 71 mg (2.8 to 3.1 mEq) of sodium and is buffered with 40 mg of dibasic sodium phosphate.  Each 250 mg capsule of oxacillin sodium contains approximately 16 mg (0.7 mEq) of sodium, and each teaspoonful of the 250 mg/5 mL oral solution contains approximately 18 mg (0.8 mEq) of sodium.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  In addition, hypokalemia has been reported rarely during therapy with the penicillinase-resistant penicillins, which may be particularly important to bear in mind when treating patients with low potassium reserves or fluid and electrolyte imbalance.  Clinical monitoring of electrolytes is recommended if these agents are used for prolonged periods.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13832, 13992, 'Oxacillin', 'Water-Electrolyte Imbalance', 'Each gram of parenteral oxacillin sodium contains approximately 64 to 71 mg (2.8 to 3.1 mEq) of sodium and is buffered with 40 mg of dibasic sodium phosphate.  Each 250 mg capsule of oxacillin sodium contains approximately 16 mg (0.7 mEq) of sodium, and each teaspoonful of the 250 mg/5 mL oral solution contains approximately 18 mg (0.8 mEq) of sodium.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  In addition, hypokalemia has been reported rarely during therapy with the penicillinase-resistant penicillins, which may be particularly important to bear in mind when treating patients with low potassium reserves or fluid and electrolyte imbalance.  Clinical monitoring of electrolytes is recommended if these agents are used for prolonged periods.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13833, 16673, 'Oxacillin', 'Water-Electrolyte Imbalance', 'Each gram of parenteral oxacillin sodium contains approximately 64 to 71 mg (2.8 to 3.1 mEq) of sodium and is buffered with 40 mg of dibasic sodium phosphate.  Each 250 mg capsule of oxacillin sodium contains approximately 16 mg (0.7 mEq) of sodium, and each teaspoonful of the 250 mg/5 mL oral solution contains approximately 18 mg (0.8 mEq) of sodium.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  In addition, hypokalemia has been reported rarely during therapy with the penicillinase-resistant penicillins, which may be particularly important to bear in mind when treating patients with low potassium reserves or fluid and electrolyte imbalance.  Clinical monitoring of electrolytes is recommended if these agents are used for prolonged periods.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13834, 16939, 'Oxacillin', 'Water-Electrolyte Imbalance', 'Each gram of parenteral oxacillin sodium contains approximately 64 to 71 mg (2.8 to 3.1 mEq) of sodium and is buffered with 40 mg of dibasic sodium phosphate.  Each 250 mg capsule of oxacillin sodium contains approximately 16 mg (0.7 mEq) of sodium, and each teaspoonful of the 250 mg/5 mL oral solution contains approximately 18 mg (0.8 mEq) of sodium.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  In addition, hypokalemia has been reported rarely during therapy with the penicillinase-resistant penicillins, which may be particularly important to bear in mind when treating patients with low potassium reserves or fluid and electrolyte imbalance.  Clinical monitoring of electrolytes is recommended if these agents are used for prolonged periods.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13835, 16940, 'Oxacillin', 'Water-Electrolyte Imbalance', 'Each gram of parenteral oxacillin sodium contains approximately 64 to 71 mg (2.8 to 3.1 mEq) of sodium and is buffered with 40 mg of dibasic sodium phosphate.  Each 250 mg capsule of oxacillin sodium contains approximately 16 mg (0.7 mEq) of sodium, and each teaspoonful of the 250 mg/5 mL oral solution contains approximately 18 mg (0.8 mEq) of sodium.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  In addition, hypokalemia has been reported rarely during therapy with the penicillinase-resistant penicillins, which may be particularly important to bear in mind when treating patients with low potassium reserves or fluid and electrolyte imbalance.  Clinical monitoring of electrolytes is recommended if these agents are used for prolonged periods.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13836, 18789, 'Oxacillin', 'Water-Electrolyte Imbalance', 'Each gram of parenteral oxacillin sodium contains approximately 64 to 71 mg (2.8 to 3.1 mEq) of sodium and is buffered with 40 mg of dibasic sodium phosphate.  Each 250 mg capsule of oxacillin sodium contains approximately 16 mg (0.7 mEq) of sodium, and each teaspoonful of the 250 mg/5 mL oral solution contains approximately 18 mg (0.8 mEq) of sodium.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  In addition, hypokalemia has been reported rarely during therapy with the penicillinase-resistant penicillins, which may be particularly important to bear in mind when treating patients with low potassium reserves or fluid and electrolyte imbalance.  Clinical monitoring of electrolytes is recommended if these agents are used for prolonged periods.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13837, 19197, 'Oxacillin', 'Water-Electrolyte Imbalance', 'Each gram of parenteral oxacillin sodium contains approximately 64 to 71 mg (2.8 to 3.1 mEq) of sodium and is buffered with 40 mg of dibasic sodium phosphate.  Each 250 mg capsule of oxacillin sodium contains approximately 16 mg (0.7 mEq) of sodium, and each teaspoonful of the 250 mg/5 mL oral solution contains approximately 18 mg (0.8 mEq) of sodium.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  In addition, hypokalemia has been reported rarely during therapy with the penicillinase-resistant penicillins, which may be particularly important to bear in mind when treating patients with low potassium reserves or fluid and electrolyte imbalance.  Clinical monitoring of electrolytes is recommended if these agents are used for prolonged periods.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13838, 19218, 'Oxacillin', 'Water-Electrolyte Imbalance', 'Each gram of parenteral oxacillin sodium contains approximately 64 to 71 mg (2.8 to 3.1 mEq) of sodium and is buffered with 40 mg of dibasic sodium phosphate.  Each 250 mg capsule of oxacillin sodium contains approximately 16 mg (0.7 mEq) of sodium, and each teaspoonful of the 250 mg/5 mL oral solution contains approximately 18 mg (0.8 mEq) of sodium.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  In addition, hypokalemia has been reported rarely during therapy with the penicillinase-resistant penicillins, which may be particularly important to bear in mind when treating patients with low potassium reserves or fluid and electrolyte imbalance.  Clinical monitoring of electrolytes is recommended if these agents are used for prolonged periods.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13839, 19222, 'Oxacillin', 'Water-Electrolyte Imbalance', 'Each gram of parenteral oxacillin sodium contains approximately 64 to 71 mg (2.8 to 3.1 mEq) of sodium and is buffered with 40 mg of dibasic sodium phosphate.  Each 250 mg capsule of oxacillin sodium contains approximately 16 mg (0.7 mEq) of sodium, and each teaspoonful of the 250 mg/5 mL oral solution contains approximately 18 mg (0.8 mEq) of sodium.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  In addition, hypokalemia has been reported rarely during therapy with the penicillinase-resistant penicillins, which may be particularly important to bear in mind when treating patients with low potassium reserves or fluid and electrolyte imbalance.  Clinical monitoring of electrolytes is recommended if these agents are used for prolonged periods.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13840, 19225, 'Oxacillin', 'Water-Electrolyte Imbalance', 'Each gram of parenteral oxacillin sodium contains approximately 64 to 71 mg (2.8 to 3.1 mEq) of sodium and is buffered with 40 mg of dibasic sodium phosphate.  Each 250 mg capsule of oxacillin sodium contains approximately 16 mg (0.7 mEq) of sodium, and each teaspoonful of the 250 mg/5 mL oral solution contains approximately 18 mg (0.8 mEq) of sodium.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  In addition, hypokalemia has been reported rarely during therapy with the penicillinase-resistant penicillins, which may be particularly important to bear in mind when treating patients with low potassium reserves or fluid and electrolyte imbalance.  Clinical monitoring of electrolytes is recommended if these agents are used for prolonged periods.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13841, 20036, 'Oxacillin', 'Water-Electrolyte Imbalance', 'Each gram of parenteral oxacillin sodium contains approximately 64 to 71 mg (2.8 to 3.1 mEq) of sodium and is buffered with 40 mg of dibasic sodium phosphate.  Each 250 mg capsule of oxacillin sodium contains approximately 16 mg (0.7 mEq) of sodium, and each teaspoonful of the 250 mg/5 mL oral solution contains approximately 18 mg (0.8 mEq) of sodium.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  In addition, hypokalemia has been reported rarely during therapy with the penicillinase-resistant penicillins, which may be particularly important to bear in mind when treating patients with low potassium reserves or fluid and electrolyte imbalance.  Clinical monitoring of electrolytes is recommended if these agents are used for prolonged periods.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13842, 24655, 'Oxacillin', 'Water-Electrolyte Imbalance', 'Each gram of parenteral oxacillin sodium contains approximately 64 to 71 mg (2.8 to 3.1 mEq) of sodium and is buffered with 40 mg of dibasic sodium phosphate.  Each 250 mg capsule of oxacillin sodium contains approximately 16 mg (0.7 mEq) of sodium, and each teaspoonful of the 250 mg/5 mL oral solution contains approximately 18 mg (0.8 mEq) of sodium.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  In addition, hypokalemia has been reported rarely during therapy with the penicillinase-resistant penicillins, which may be particularly important to bear in mind when treating patients with low potassium reserves or fluid and electrolyte imbalance.  Clinical monitoring of electrolytes is recommended if these agents are used for prolonged periods.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13843, 0, 'Oxandrolone', 'Prostatic Neoplasms', 'The use of androgenic anabolic steroids is contraindicated for male patients with carcinoma of the breast or prostate.  Circulating androgens can be converted in peripheral tissues to estrogens and dihydrotestosterone, which may act as promoters of tumor growth in the breast and prostate, respectively.  Likewise, androgenic agents may cause enlargement of the prostate and should be used cautiously in patients with or predisposed to prostatic hypertrophy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13844, 0, 'Oxandrolone', 'Water-Electrolyte Imbalance', 'Androgenic anabolic steroids may cause sodium and water retention, particularly when given in high dosages or for prolonged periods.  Therapy with these agents should be administered cautiously in patients who have preexisting problems with fluid overload or are at risk for developing edema.  The manufacturers consider the use of androgenic agents to be contraindicated in patients with severe cardiac, renal and/or hepatic dysfunction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13845, 0, 'Oxandrolone', 'Breast Neoplasms', 'When treated with androgenic anabolic steroids, patients with metastatic breast cancer may develop hypercalcemia due to osteolysis.  Frequent determination of urine and serum calcium levels is recommended during therapy with androgenic agents.  If hypercalcemia occurs, therapy should be stopped.  The development of hypercalcemia may indicate progression of metastases to the bone.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13846, 0, 'Oxandrolone', 'Hyperlipoproteinemias', 'Androgenic anabolic steroids may adversely affect serum lipids, including lowering HDL and elevating LDL levels.  These changes can be marked, particularly with the 17-alpha-alkyl derivatives (i.e., fluoxymesterone, methyltestosterone, oxandrolone, oxymetholone, and stanozolol), and may significantly impact the risk of atherosclerosis and coronary artery disease.  Patients with preexisting hyperlipoproteinemia may require closer monitoring during therapy with androgenic agents, and adjustments made accordingly in their lipid-lowering regimen.  Androgen therapy should be administered cautiously in patients with coronary artery disease or a history of ischemic heart disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13847, 0, 'Oxandrolone', 'Liver Diseases', 'The use of androgenic anabolic steroids may be associated with development of cholestatic hepatitis and jaundice.  Other, more serious hepatotoxicities such as peliosis hepatis and hepatocellular neoplasms are rare but may occur with prolonged use or high dosages.  These latter toxicities may be fatal and often not recognized until they become life-threatening.  Patients with preexisting liver diseases should be monitored more closely during therapy with anabolic steroids if they are used.  If liver function declines or toxicity occurs, therapy should be withdrawn and the cause investigated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13848, 0, 'Oxandrolone', 'Polycythemia', 'Androgenic anabolic steroids may cause polycythemia when given in high dosages or for prolonged periods.  Patients with preexisting polycythemia may experience worsening of their condition.  Frequent monitoring of clinical status and hemoglobin and hematocrit levels is recommended if androgen therapy is administered to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13849, 0, 'Oxandrolone', 'Blood Coagulation Disorders', 'Androgenic anabolic steroids may cause suppression of clotting factors II, V, VII, and X, and an increase in prothrombin time.  Androgen therapy should be administered cautiously in patients with bleeding disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13850, 0, 'Oxandrolone', 'Diabetes Mellitus', 'The metabolic effects of androgenic anabolic steroids may lower blood glucose.  Decreased glucose tolerance and increased insulin resistance have also been reported.  Patients with diabetes mellitus should be monitored more closely during therapy with androgenic agents, and their antidiabetic regimen adjusted accordingly.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13851, 0, 'Oxandrolone', 'Hypercalcemia', 'Androgenic anabolic steroids decrease urinary excretion of calcium, which may result in hypercalcemia.  Therapy with androgenic agents should be administered cautiously in patients with hypercalcemia, disorders of bone metabolism such as hyperparathyroidism, or renal dysfunction.  Some manufacturers consider the use of androgenic anabolic steroids to be contraindicated in patients with hypercalcemia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13852, 0, 'Oxandrolone', 'Thyroid Diseases', 'When androgenic anabolic steroids are used in patients with thyroid disorders, clinicians should be aware that these agents may affect thyroid function tests.  Specifically, thyroid-binding globulin levels may be decreased, resulting in lower total T4 serum levels and increased resin uptake of T3 and T4.  Free thyroid hormone levels remain unchanged, however.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13853, 27865, 'Osimertinib', 'Cardiomyopathies', 'Cardiomyopathy was observed in clinical trials of certain EGFR inhibitors.  Assess Left Ventricular Ejection Fraction (LVEF) by echocardiogram or multigated acquisition (MUGA) scan before initiation of these agents and then at 3 month intervals while on treatment.  Caution is recommended when prescribing these agents to patients with conditions that could impair left ventricular function and it is recommended to withhold treatment with these agents if ejection fraction drops below the established lower limit of normal.  For symptomatic congestive heart failure or persistent, asymptomatic LV dysfunction that does not resolve within 4 weeks, permanently discontinue these agents.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13854, 27866, 'Osimertinib', 'Cardiomyopathies', 'Cardiomyopathy was observed in clinical trials of certain EGFR inhibitors.  Assess Left Ventricular Ejection Fraction (LVEF) by echocardiogram or multigated acquisition (MUGA) scan before initiation of these agents and then at 3 month intervals while on treatment.  Caution is recommended when prescribing these agents to patients with conditions that could impair left ventricular function and it is recommended to withhold treatment with these agents if ejection fraction drops below the established lower limit of normal.  For symptomatic congestive heart failure or persistent, asymptomatic LV dysfunction that does not resolve within 4 weeks, permanently discontinue these agents.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13855, 27865, 'Osimertinib', 'Stevens-Johnson Syndrome', 'Cutaneous reactions, in some cases severe, have been reported with the use of EGFR inhibitors.  Monitor patients who develop dermatologic or soft tissue toxicities while receiving these agents for the development of inflammatory or infectious sequelae.  It is recommended to withhold treatment, and appropriate measures should be instituted as appropriate or discontinue the use of these agents for dermatologic or soft tissue toxicity associated with severe or life-threatening inflammatory or infectious complications.  Advise patients to wear sunscreen and hats and limit sun exposure while receiving therapy with these agents as exposure to sunlight can exacerbate dermatologic toxicities.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13856, 27866, 'Osimertinib', 'Stevens-Johnson Syndrome', 'Cutaneous reactions, in some cases severe, have been reported with the use of EGFR inhibitors.  Monitor patients who develop dermatologic or soft tissue toxicities while receiving these agents for the development of inflammatory or infectious sequelae.  It is recommended to withhold treatment, and appropriate measures should be instituted as appropriate or discontinue the use of these agents for dermatologic or soft tissue toxicity associated with severe or life-threatening inflammatory or infectious complications.  Advise patients to wear sunscreen and hats and limit sun exposure while receiving therapy with these agents as exposure to sunlight can exacerbate dermatologic toxicities.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13857, 27865, 'Osimertinib', 'Eye Diseases', 'Some epidermal growth factor receptor (EGFR) inhibitors should be administered cautiously in patients with ocular disorders such as primary keratitis, ulcerative keratitis, or conjunctivitis.  It is recommended to interrupt or discontinue treatment with these agents if patients present with acute or worsening ocular disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13858, 27866, 'Osimertinib', 'Eye Diseases', 'Some epidermal growth factor receptor (EGFR) inhibitors should be administered cautiously in patients with ocular disorders such as primary keratitis, ulcerative keratitis, or conjunctivitis.  It is recommended to interrupt or discontinue treatment with these agents if patients present with acute or worsening ocular disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13859, 27865, 'Osimertinib', 'Lung Diseases', 'The use of certain EGFR inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation.  If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13860, 27866, 'Osimertinib', 'Lung Diseases', 'The use of certain EGFR inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation.  If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13861, 27865, 'Osimertinib', 'Long QT Syndrome', 'QT prolongation was observed in patients treated with certain EGFR inhibitors.  These agents should be administered with caution in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval.  Serum electrolytes should be corrected prior to initiating therapy with these agents.  Periodic monitoring of ECGs and electrolytes is recommended in these patients.  Permanently discontinue the use of these agents in patients who develop QTc interval prolongation with signs/symptoms of life-threatening arrhythmia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13862, 27866, 'Osimertinib', 'Long QT Syndrome', 'QT prolongation was observed in patients treated with certain EGFR inhibitors.  These agents should be administered with caution in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval.  Serum electrolytes should be corrected prior to initiating therapy with these agents.  Periodic monitoring of ECGs and electrolytes is recommended in these patients.  Permanently discontinue the use of these agents in patients who develop QTc interval prolongation with signs/symptoms of life-threatening arrhythmia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13863, 27865, 'Osimertinib', 'Hepatic Insufficiency', 'No formal pharmacokinetic studies of osimertinib have been conducted in patients with renal or hepatic impairment.  Based on population pharmacokinetic (PK) analysis of osimertinib, no dose adjustment is recommended in patients with mild (CrCl 60-89 mL/min) or moderate (CrCl 30-59 mL/min) renal impairment, or mild hepatic impairment (total bilirubin <ULN and AST between 1 to 1.5 times the ULN or total bilirubin between 1.0 to 1.5 times ULN and any AST ).  There are no data on the pharmacokinetics of osimertinib in patients with severe renal impairment (CrCl less than 30 mL/min) or with moderate to severe hepatic impairment (moderate:  total bilirubin between 1.5 to 3.0 times ULN and any AST, and severe:  total bilirubin between 3.0-10 times ULN and any AST).  Close monitoring is recommended for these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13864, 27866, 'Osimertinib', 'Hepatic Insufficiency', 'No formal pharmacokinetic studies of osimertinib have been conducted in patients with renal or hepatic impairment.  Based on population pharmacokinetic (PK) analysis of osimertinib, no dose adjustment is recommended in patients with mild (CrCl 60-89 mL/min) or moderate (CrCl 30-59 mL/min) renal impairment, or mild hepatic impairment (total bilirubin <ULN and AST between 1 to 1.5 times the ULN or total bilirubin between 1.0 to 1.5 times ULN and any AST ).  There are no data on the pharmacokinetics of osimertinib in patients with severe renal impairment (CrCl less than 30 mL/min) or with moderate to severe hepatic impairment (moderate:  total bilirubin between 1.5 to 3.0 times ULN and any AST, and severe:  total bilirubin between 3.0-10 times ULN and any AST).  Close monitoring is recommended for these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13865, 24385, 'Oxaprozin', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13866, 24386, 'Oxaprozin', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13867, 24385, 'Oxaprozin', 'Water-Electrolyte Imbalance', 'Fluid retention and edema have been reported in association with the use of nonsteroidal anti-inflammatory drugs (NSAIDs).  Therapy with NSAIDs should be administered cautiously in patients with preexisting fluid retention, hypertension, or a history of heart failure.  Blood pressure and cardiovascular status should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13868, 24386, 'Oxaprozin', 'Water-Electrolyte Imbalance', 'Fluid retention and edema have been reported in association with the use of nonsteroidal anti-inflammatory drugs (NSAIDs).  Therapy with NSAIDs should be administered cautiously in patients with preexisting fluid retention, hypertension, or a history of heart failure.  Blood pressure and cardiovascular status should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13869, 24385, 'Oxaprozin', 'Peptic Ulcer', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal.  These serious adverse events can develop at any time, with or without warning symptoms.  Only 1 in 5 patients who develop a serious upper GI side effect on NSAIDs is symptomatic.  NSAIDs should be used with caution in patients with history of peptic ulcer disease and/or GI bleeding, as these patients had a greater than 10-fold increased risk for developing a GI bleed compared to patients without these risk factors.  Caution is also advised if NSAIDs are prescribed to patients with other factors that increase risk of GI bleeding, such as:  prolonged NSAID therapy; concomitant use of oral corticosteroids, antiplatelet agents (e.g., aspirin), anticoagulants, selective serotonin reuptake inhibitors; alcohol use; smoking; history of gastrointestinal surgery or anastomosis, older age; poor general health status; and advanced liver disease and/or coagulopathy.  Particular vigilance is necessary when treating elderly or debilitated patients since most postmarketing reports of fatal GI events occurred in these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13870, 24386, 'Oxaprozin', 'Peptic Ulcer', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal.  These serious adverse events can develop at any time, with or without warning symptoms.  Only 1 in 5 patients who develop a serious upper GI side effect on NSAIDs is symptomatic.  NSAIDs should be used with caution in patients with history of peptic ulcer disease and/or GI bleeding, as these patients had a greater than 10-fold increased risk for developing a GI bleed compared to patients without these risk factors.  Caution is also advised if NSAIDs are prescribed to patients with other factors that increase risk of GI bleeding, such as:  prolonged NSAID therapy; concomitant use of oral corticosteroids, antiplatelet agents (e.g., aspirin), anticoagulants, selective serotonin reuptake inhibitors; alcohol use; smoking; history of gastrointestinal surgery or anastomosis, older age; poor general health status; and advanced liver disease and/or coagulopathy.  Particular vigilance is necessary when treating elderly or debilitated patients since most postmarketing reports of fatal GI events occurred in these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13871, 24385, 'Oxaprozin', 'Exanthema', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious skin adverse reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, and exfoliative dermatitis), which can be fatal.  These serious events may occur without warning.  Patients should be advised to discontinue the NSAID and seek medical attention promptly at the first sign of skin rash or any other sign of hypersensitivity.  NSAIDs are contraindicated in patients with previous serious skin reactions to these drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13872, 24386, 'Oxaprozin', 'Exanthema', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious skin adverse reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, and exfoliative dermatitis), which can be fatal.  These serious events may occur without warning.  Patients should be advised to discontinue the NSAID and seek medical attention promptly at the first sign of skin rash or any other sign of hypersensitivity.  NSAIDs are contraindicated in patients with previous serious skin reactions to these drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13873, 24385, 'Oxaprozin', 'Kidney Diseases', 'Long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) has resulted in renal papillary necrosis and other renal injury.  Renal toxicity has been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion:  in such patients, NSAIDs may cause a dose-dependent reduction in prostaglandin synthesis and, secondarily, in renal blood flow, which may precipitate overt renal decompensation.  Patients at greatest risk for this reaction include the elderly, those with impaired renal function, dehydration, hypovolemia, heart failure, or liver dysfunction, and those taking diuretics, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers; discontinuation of NSAID therapy will usually lead to recovery to the pretreatment state.  No information is available regarding use NSAIDs in patients with advanced renal disease; the renal effects of NSAIDs may hasten the progression of renal dysfunction in patients with preexisting renal disease.  Volume status should be corrected in dehydrated or hypovolemic patients prior to initiating treatment.  Renal function should be monitored during therapy in patients with renal or liver dysfunction, heart failure, dehydration, or hypovolemia.  NSAIDs should be avoided in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function; if an NSAID is used in such patients, they should be monitored for signs of worsening renal function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13874, 24386, 'Oxaprozin', 'Kidney Diseases', 'Long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) has resulted in renal papillary necrosis and other renal injury.  Renal toxicity has been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion:  in such patients, NSAIDs may cause a dose-dependent reduction in prostaglandin synthesis and, secondarily, in renal blood flow, which may precipitate overt renal decompensation.  Patients at greatest risk for this reaction include the elderly, those with impaired renal function, dehydration, hypovolemia, heart failure, or liver dysfunction, and those taking diuretics, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers; discontinuation of NSAID therapy will usually lead to recovery to the pretreatment state.  No information is available regarding use NSAIDs in patients with advanced renal disease; the renal effects of NSAIDs may hasten the progression of renal dysfunction in patients with preexisting renal disease.  Volume status should be corrected in dehydrated or hypovolemic patients prior to initiating treatment.  Renal function should be monitored during therapy in patients with renal or liver dysfunction, heart failure, dehydration, or hypovolemia.  NSAIDs should be avoided in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function; if an NSAID is used in such patients, they should be monitored for signs of worsening renal function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13875, 24385, 'Oxaprozin', 'Thrombosis', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.  This risk may occur early in treatment and may increase with duration of use.  Clinical trials of several cyclooxygenase-2 (COX-2) selective and nonselective NSAIDs of up to 3 years duration have supported this increased risk.  It is unclear from available data if the risk for cardiovascular thrombotic events is similar for all NSAIDs.  Therapy with NSAIDs should be administered cautiously in patients with a history of cardiovascular or cerebrovascular disease.  Patients should be treated with the lowest effective dosage for the shortest duration necessary.  Appropriate antiplatelet therapy should be administered to patients requiring cardioprotection; however, there is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious cardiovascular thrombotic events associated with NSAID use, while the risk of serious gastrointestinal events is increased.  Physicians and patients should remain alert for the development of adverse cardiovascular events throughout the entire duration of therapy, even without prior cardiovascular symptoms.  Patients should be advised to promptly seek medical attention if they experience symptoms of cardiovascular thrombotic events (including chest pain, shortness of breath, weakness, or slurring of speech).NSAIDs are contraindicated in the setting of coronary artery bypass graft (CABG) surgery.  Two large clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10 to 14 days following CABG surgery found an increased incidence of myocardial infarction and stroke.The use of NSAIDs should be avoided in patients with a recent myocardial infarction unless the benefits are expected to outweigh the risk of recurrent cardiovascular thrombotic events.  If an NSAID is used in patients with a recent myocardial infarction, they should be monitored for signs of cardiac ischemia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13876, 24386, 'Oxaprozin', 'Thrombosis', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.  This risk may occur early in treatment and may increase with duration of use.  Clinical trials of several cyclooxygenase-2 (COX-2) selective and nonselective NSAIDs of up to 3 years duration have supported this increased risk.  It is unclear from available data if the risk for cardiovascular thrombotic events is similar for all NSAIDs.  Therapy with NSAIDs should be administered cautiously in patients with a history of cardiovascular or cerebrovascular disease.  Patients should be treated with the lowest effective dosage for the shortest duration necessary.  Appropriate antiplatelet therapy should be administered to patients requiring cardioprotection; however, there is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious cardiovascular thrombotic events associated with NSAID use, while the risk of serious gastrointestinal events is increased.  Physicians and patients should remain alert for the development of adverse cardiovascular events throughout the entire duration of therapy, even without prior cardiovascular symptoms.  Patients should be advised to promptly seek medical attention if they experience symptoms of cardiovascular thrombotic events (including chest pain, shortness of breath, weakness, or slurring of speech).NSAIDs are contraindicated in the setting of coronary artery bypass graft (CABG) surgery.  Two large clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10 to 14 days following CABG surgery found an increased incidence of myocardial infarction and stroke.The use of NSAIDs should be avoided in patients with a recent myocardial infarction unless the benefits are expected to outweigh the risk of recurrent cardiovascular thrombotic events.  If an NSAID is used in patients with a recent myocardial infarction, they should be monitored for signs of cardiac ischemia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13877, 24385, 'Oxaprozin', 'Anemia', 'Anemia has been reported in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  This may be due to fluid retention, occult/gross blood loss, or an incompletely described effect on erythropoiesis.  Hemoglobin or hematocrit should be monitored in patients with any signs/symptoms of anemia or blood loss, especially during long-term therapy.  NSAIDs may increase risk of bleeding events; comorbid conditions (e.g., coagulation disorders; concomitant use of warfarin/other anticoagulants, antiplatelet agents, serotonin/serotonin norepinephrine reuptake inhibitors) may increase this risk, and patients with these conditions should be monitored for signs of bleeding.  Therapy with NSAIDs should be administered cautiously in patients with or predisposed to anemia.  Clinical monitoring of hematopoietic function may be appropriate, particularly during chronic therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13878, 24386, 'Oxaprozin', 'Anemia', 'Anemia has been reported in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  This may be due to fluid retention, occult/gross blood loss, or an incompletely described effect on erythropoiesis.  Hemoglobin or hematocrit should be monitored in patients with any signs/symptoms of anemia or blood loss, especially during long-term therapy.  NSAIDs may increase risk of bleeding events; comorbid conditions (e.g., coagulation disorders; concomitant use of warfarin/other anticoagulants, antiplatelet agents, serotonin/serotonin norepinephrine reuptake inhibitors) may increase this risk, and patients with these conditions should be monitored for signs of bleeding.  Therapy with NSAIDs should be administered cautiously in patients with or predisposed to anemia.  Clinical monitoring of hematopoietic function may be appropriate, particularly during chronic therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13879, 24385, 'Oxaprozin', 'Heart Failure', 'Fluid retention and edema have been observed in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs), including some topical formulations.  These drugs should be avoided in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure.  If an NSAID is used in patients with severe heart failure, they should be monitored for signs of worsening heart failure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13880, 24386, 'Oxaprozin', 'Heart Failure', 'Fluid retention and edema have been observed in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs), including some topical formulations.  These drugs should be avoided in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure.  If an NSAID is used in patients with severe heart failure, they should be monitored for signs of worsening heart failure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13881, 24385, 'Oxaprozin', 'Liver Diseases', 'Borderline elevations of 1 or more liver tests may occur in up to 15% of patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  These laboratory abnormalities may progress, remain unchanged, or regress with continuing therapy.  Elevations of ALT or AST (at least 3 times the upper limit of normal) have been reported in about 1% of patients in clinical trials.  In addition, rare (sometimes fatal) cases of severe hepatotoxicity, including liver necrosis, hepatic failure, jaundice, and fulminant hepatitis have been reported.  Therapy with NSAIDs should be administered cautiously in patients with preexisting liver disease.  Periodic monitoring of liver function is recommended during prolonged therapy.  NSAIDs are also highly protein-bound and some are extensively metabolized by the liver.  Metabolic activity and/or plasma protein binding may be altered in patients with hepatic impairment.  A dosage reduction may be required in some cases.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13882, 24386, 'Oxaprozin', 'Liver Diseases', 'Borderline elevations of 1 or more liver tests may occur in up to 15% of patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  These laboratory abnormalities may progress, remain unchanged, or regress with continuing therapy.  Elevations of ALT or AST (at least 3 times the upper limit of normal) have been reported in about 1% of patients in clinical trials.  In addition, rare (sometimes fatal) cases of severe hepatotoxicity, including liver necrosis, hepatic failure, jaundice, and fulminant hepatitis have been reported.  Therapy with NSAIDs should be administered cautiously in patients with preexisting liver disease.  Periodic monitoring of liver function is recommended during prolonged therapy.  NSAIDs are also highly protein-bound and some are extensively metabolized by the liver.  Metabolic activity and/or plasma protein binding may be altered in patients with hepatic impairment.  A dosage reduction may be required in some cases.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13883, 24385, 'Oxaprozin', 'Hyperkalemia', 'Increases in serum potassium concentration (including hyperkalemia) have been reported with use of nonsteroidal anti-inflammatory drugs (NSAIDs), even in some patients without renal impairment.  In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state.  Caution is advised in patients with hyperkalemia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13884, 24386, 'Oxaprozin', 'Hyperkalemia', 'Increases in serum potassium concentration (including hyperkalemia) have been reported with use of nonsteroidal anti-inflammatory drugs (NSAIDs), even in some patients without renal impairment.  In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state.  Caution is advised in patients with hyperkalemia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13885, 24385, 'Oxaprozin', 'Hypertension', 'Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events.  NSAIDs should be used with caution in patients with hypertension.  Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13886, 24386, 'Oxaprozin', 'Hypertension', 'Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events.  NSAIDs should be used with caution in patients with hypertension.  Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13887, 24385, 'Oxaprozin', 'Blood Platelet Disorders', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) reversibly inhibit platelet adhesion and aggregation and may prolong bleeding time in some patients.  With the exception of aspirin, the platelet effects seen with most NSAIDs at usual recommended dosages are generally slight and of relatively short duration but may be more pronounced in patients with underlying hemostatic abnormalities.  Thrombocytopenia has also been reported rarely during NSAID use.  Therapy with NSAIDs should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  NSAIDs that selectively inhibit cyclooxygenase-2 (i.e., COX-2 inhibitors) do not appear to affect platelet function or bleeding time at indicated dosages and may be preferable if risk of bleeding is a concern.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13888, 24386, 'Oxaprozin', 'Blood Platelet Disorders', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) reversibly inhibit platelet adhesion and aggregation and may prolong bleeding time in some patients.  With the exception of aspirin, the platelet effects seen with most NSAIDs at usual recommended dosages are generally slight and of relatively short duration but may be more pronounced in patients with underlying hemostatic abnormalities.  Thrombocytopenia has also been reported rarely during NSAID use.  Therapy with NSAIDs should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  NSAIDs that selectively inhibit cyclooxygenase-2 (i.e., COX-2 inhibitors) do not appear to affect platelet function or bleeding time at indicated dosages and may be preferable if risk of bleeding is a concern.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13889, 1109, 'Atropine', 'Diabetic Neuropathies', 'Agents with anticholinergic activity can exacerbate many of the manifestations of autonomic neuropathy, including tachycardia, anhidrosis, bladder atony, obstipation, dry mouth and eyes, cycloplegia and blurring of vision, and sexual impotence in males.  Therapy with antimuscarinic agents and higher dosages of antispasmodic agents (e.g., dicyclomine or oxybutynin) should be administered cautiously in patients with autonomic neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13890, 1110, 'Atropine', 'Diabetic Neuropathies', 'Agents with anticholinergic activity can exacerbate many of the manifestations of autonomic neuropathy, including tachycardia, anhidrosis, bladder atony, obstipation, dry mouth and eyes, cycloplegia and blurring of vision, and sexual impotence in males.  Therapy with antimuscarinic agents and higher dosages of antispasmodic agents (e.g., dicyclomine or oxybutynin) should be administered cautiously in patients with autonomic neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13891, 1111, 'Atropine', 'Diabetic Neuropathies', 'Agents with anticholinergic activity can exacerbate many of the manifestations of autonomic neuropathy, including tachycardia, anhidrosis, bladder atony, obstipation, dry mouth and eyes, cycloplegia and blurring of vision, and sexual impotence in males.  Therapy with antimuscarinic agents and higher dosages of antispasmodic agents (e.g., dicyclomine or oxybutynin) should be administered cautiously in patients with autonomic neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13892, 6629, 'Atropine', 'Diabetic Neuropathies', 'Agents with anticholinergic activity can exacerbate many of the manifestations of autonomic neuropathy, including tachycardia, anhidrosis, bladder atony, obstipation, dry mouth and eyes, cycloplegia and blurring of vision, and sexual impotence in males.  Therapy with antimuscarinic agents and higher dosages of antispasmodic agents (e.g., dicyclomine or oxybutynin) should be administered cautiously in patients with autonomic neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13893, 14591, 'Atropine', 'Diabetic Neuropathies', 'Agents with anticholinergic activity can exacerbate many of the manifestations of autonomic neuropathy, including tachycardia, anhidrosis, bladder atony, obstipation, dry mouth and eyes, cycloplegia and blurring of vision, and sexual impotence in males.  Therapy with antimuscarinic agents and higher dosages of antispasmodic agents (e.g., dicyclomine or oxybutynin) should be administered cautiously in patients with autonomic neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13894, 14592, 'Atropine', 'Diabetic Neuropathies', 'Agents with anticholinergic activity can exacerbate many of the manifestations of autonomic neuropathy, including tachycardia, anhidrosis, bladder atony, obstipation, dry mouth and eyes, cycloplegia and blurring of vision, and sexual impotence in males.  Therapy with antimuscarinic agents and higher dosages of antispasmodic agents (e.g., dicyclomine or oxybutynin) should be administered cautiously in patients with autonomic neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13895, 1109, 'Atropine', 'Intestinal Obstruction', 'Anticholinergics are contraindicated in patients with obstructive diseases such as achalasia, esophageal stricture or stenosis, pyloroduodenal stenosis, stenosing peptic ulcer, pyloric obstruction, and paralytic ileus.  Anticholinergics may further suppress intestinal motility with resultant precipitation or aggravation of toxic megacolon.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13896, 1110, 'Atropine', 'Intestinal Obstruction', 'Anticholinergics are contraindicated in patients with obstructive diseases such as achalasia, esophageal stricture or stenosis, pyloroduodenal stenosis, stenosing peptic ulcer, pyloric obstruction, and paralytic ileus.  Anticholinergics may further suppress intestinal motility with resultant precipitation or aggravation of toxic megacolon.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13897, 1111, 'Atropine', 'Intestinal Obstruction', 'Anticholinergics are contraindicated in patients with obstructive diseases such as achalasia, esophageal stricture or stenosis, pyloroduodenal stenosis, stenosing peptic ulcer, pyloric obstruction, and paralytic ileus.  Anticholinergics may further suppress intestinal motility with resultant precipitation or aggravation of toxic megacolon.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13898, 6629, 'Atropine', 'Intestinal Obstruction', 'Anticholinergics are contraindicated in patients with obstructive diseases such as achalasia, esophageal stricture or stenosis, pyloroduodenal stenosis, stenosing peptic ulcer, pyloric obstruction, and paralytic ileus.  Anticholinergics may further suppress intestinal motility with resultant precipitation or aggravation of toxic megacolon.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13899, 14591, 'Atropine', 'Intestinal Obstruction', 'Anticholinergics are contraindicated in patients with obstructive diseases such as achalasia, esophageal stricture or stenosis, pyloroduodenal stenosis, stenosing peptic ulcer, pyloric obstruction, and paralytic ileus.  Anticholinergics may further suppress intestinal motility with resultant precipitation or aggravation of toxic megacolon.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13900, 14592, 'Atropine', 'Intestinal Obstruction', 'Anticholinergics are contraindicated in patients with obstructive diseases such as achalasia, esophageal stricture or stenosis, pyloroduodenal stenosis, stenosing peptic ulcer, pyloric obstruction, and paralytic ileus.  Anticholinergics may further suppress intestinal motility with resultant precipitation or aggravation of toxic megacolon.', '3', '', 'DDInter', 0);
